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Abstract
Tumor necrosis factor-α (TNF-α) is a key mediator of inflammatory diseases, including rheumatoid
arthritis (RA), and anti–TNF-α drugs such as etanercept are effective treatments. Splice-switching
oligonucleotides (SSOs) are a new class of drugs designed to induce therapeutically favorable splice
variants of targeted genes. In this work, we used locked nucleic acid (LNA)–based SSOs to modulate
splicing of TNF receptor 2 (TNFR2) pre-mRNA. The SSO induced skipping of TNFR2 exon 7, which
codes the transmembrane domain (TM), switching endogenous expression from the membrane-
bound, functional form to a soluble, secreted form (Δ7TNFR2). This decoy receptor protein
accumulated in the circulation of treated mice, antagonized TNF-α, and altered disease in two mouse
models: TNF-α-induced hepatitis and collagen-induced arthritis (CIA). This is the first report of
upregulation of the endogenous, circulating TNF-α antagonist by oligonucleotide-induced splicing
modulation.
Introduction
Tumor necrosis factor-α (TNF-α) is a key cytokine in rheumatoid arthritis (RA) and other
inflammatory diseases.1 Currently available anti–TNF-α biological drugs such as etanercept,
a dimerized TNF receptor 2 (TNFR2) receptor:Fc fusion protein, and anti–TNF-α monoclonal
antibodies, infliximab and adalimumab, bind TNF-α and block its inflammatory effects.2 TNF-
α activity is mediated through two membrane-bound receptors, TNFR1 and TNFR2.1 In
response to TNF-α exposure, both are downregulated by metalloprotease-induced shedding of
the extracellular domains (ECDs), which bind TNF-α very poorly. Downregulation of TNFR2
is also achieved by alternative splicing to the soluble Δ7/8TNFR2 form, which is upregulated
in the inflammatory state,3 and lacks exons 7 and 8; exon 7 encodes the transmembrane domain
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(TM). The modest upregulation of Δ7/8TNFR2 in patients is evidently not sufficient to
abrogate the inflammatory effects of TNF-α in RA.
The induction of exon skipping or other alternative splicing pathways by splice-switching
oligonucleotides (SSOs) is a technology in which splice variants may be produced as potential
therapeutics.4–7 Unlike antisense downregulation of gene expression via RNase H or RNA
interference degradation pathways, SSOs modulate alternative splicing of targeted pre-mRNA,
upregulating expression of desirable protein isoforms, while simultaneously downregulating
undesirable isoforms. Modified oligonucleotide backbones in SSOs prevent pre-mRNA
degradation by RNase H, impart high specificity toward their target sequences, and increase
resistance to nucleases in intracellular and serum environments.
The effectiveness of SSOs has been demonstrated in cell culture against several target genes.
8–16 Systemic SSO delivery in vivo, initially in a transgenic mouse model of alternative/
aberrant splicing,17 or against endogenous MyD88 and Duchenne muscular dystrophy target
pre-mRNAs, demonstrated the functional and therapeutic consequences of splicing
modulation.18–20 Most recently, in a clinical trial, intramuscularly delivered SSOs restored
dystrophin expression in Duchenne muscular dystrophy patients.21 This rapidly expanding
field was recently reviewed in detail.4
In vivo, depending on their chemical composition, there are significant differences in the
functional tissue distribution and potency of SSOs.17 Recent studies showed that locked
nucleic acids (LNAs)/phosphorothioate backbone SSOs had extremely high potency in the
liver.22 The high activity of LNA SSOs in the liver, the fact that TNFR2 is expressed in the
liver, and that exon 7 alone codes for the TM, led us to hypothesize that LNA SSOs targeted
to exon 7 of TNFR2 pre-mRNA would shift splicing in the nucleus of hepatocytes, upregulating
the Δ7TNFR2 protein, which would be secreted from the liver and accumulate in the circulation
of treated animals (Figure 1), while simultaneously downregulating functional, membrane-
bound liver TNFR2. Thus, the SSOs would instruct the liver to become a “factory” for the
production of the soluble TNF-α antagonist, Δ7TNFR2 protein. Here we show that the “liver
as a factory” approach yields, in a dose- and sequence-specific manner, biologically significant
levels of Δ7TNFR2 and anti–TNF-α activity in the blood of SSO-treated mice, which reduced
TNF-α-induced hepatitis23 and collagen-induced arthritis (CIA).24
Results
Induction and anti–TNF-α activity of SSO-induced soluble Δ7TNFR2 protein
To induce murine Δ7TNFR2 protein, a series of LNA SSOs targeted to exon 7 sequences was
designed and screened for splicing modulation in mouse L929 cells (Figure 2a). The observed
positional effects presumably reflect the relative ability of the SSO to block the interaction of
the splicing machinery with sequence elements (e.g., splice sites or exonic splicing enhancer).
4 From this screen of just 12 SSO, LNA SSO3274, which specifically and potently shifted
TNFR2 splicing to the Δ7TNFR2 isoform, was identified and used for further investigation in
vivo. SSO3305, which also yielded significant splice switching, was not chosen because it
interfered with reverse transcription–PCR of the full-length TNFR2 messenger RNA (mRNA)
and because it induced lower Δ7TNFR2 protein than SSO3274 (Supplementary Figures S1
and S2).
The Δ7TNFR2 protein is structurally very similar to the soluble TNFR2 protein lacking the
TM protein constructed by Moosmayer et al. (P80TM-), which has high affinity to TNF-α, due
to dimerization via the intracellular domain.25 Unlike the monomeric, naturally shed TNFR2
ECD present in the sera of untreated animals, soluble secreted Δ7TNFR2 contains both the
ECD and intracellular domain, with the most of the TM deleted by exon 7 skipping (see Figure
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1). We exploited this difference to develop an enzyme-linked immunosorbent assay (ELISA)
that specifically detects Δ7TNFR2 protein in serum, while eliminating the signal from the shed
ECD, by using a capture antibody that recognizes the intracellular domain, and a detection
antibody that recognizes the ECD (see Materials and Methods and Supplementary Figure S3).
Thus, Δ7TNFR2 was detected from a zero background, indicating that Δ7TNFR2 is not
naturally expressed at the mRNA or protein level (see Figure 2) and is only induced by SSO
treatment. This highly specific assay was used in the experiments described below to accurately
measure Δ7TNFR2 protein induction by SSO3274 in vivo.
Mice were injected once daily with LNA SSO3274 at 25 mg/kg/day intraperitoneally (IP) for
5 days and bled 5–35 days after the last injection. SSO3274 induced 8,000–10,000 pg/ml of
Δ7TNFR2, which, remarkably, remained detectable in the circulation for 35 days (Figure 2b).
The protein production corresponded to a strong shift in TNFR2 splicing detected in liver RNA
isolated at the indicated days at the time of killing (Figure 2b, bottom); SSO3274 produced no
liver toxicity (Supplementary Figure S4). Small intestine and colon also showed Δ7TNFR2
induction after SSO3274 treatment; however the liver, due to its size, TNFR2 expression level,
and the degree of splice shifting, is likely the main contributor of circulating Δ7TNFR2
(Supplementary Figure S5). These data agree with previous biodistribution studies for LNA
SSOs, which show liver as one of the tissues that accumulate the most compound.22
To quantify the anti–TNF-α activity in the sera of LNA SSO3274–treated mice, a classical
L929 cell-based cytotoxicity assay was employed. This assay showed that cell treatment with
TNF-α plus the serum from mice receiving no or control SSOs led to ∼80% cell kill (20% cell
survival), reflecting no anti–TNF-α activity (Figure 3a). Importantly, cells treated with TNF-
α plus the serum collected 5 or 27 days after mouse injections with SSO3274 (Figure 3a, TNF
+ 3274) showed ∼60% cell survival, indicating that the soluble Δ7TNFR2 protein in the serum
acted as a TNF-α antagonist, binding to and inactivating the TNF-α, and preventing its cytotoxic
effect on the L929 cells. Overall, these data indicate that the induced Δ7TNFR2 TNF-α
antagonist remained active in the circulation of treated mice for at least 27 days after SSO
treatment.
To confirm that the observed effects of Δ7TNFR2 are caused by direct binding to TNF-α, and
not a nonspecific phenomenon, we added increasing concentrations of an inactivating, anti-
TNFR2 antibody, that competes with TNF-α for binding to Δ7TNFR2. The anti-TNFR2
antibody itself was not toxic, and as expected, prevented Δ7TNFR2 protein from binding TNF-
α, neutralizing the protective effect of Δ7TNFR2 in the L929 cytotoxicity assay, in a dose-
dependent manner (Figure 3b).
The potency of the Δ7TNFR2 protein was compared with that of etanercept, an approved anti–
TNF-α drug. Etanercept was injected into mice at 50 μg, IP once daily for 5 days. Serum from
SSO- or etanercept-treated mice was diluted with serum from untreated mice, and the anti–
TNF-α activity was plotted versus mouse Δ7TNFR2 or etanercept protein concentration,
respectively. Figure 3c shows that in vivo, the half maximal effective concentration (EC50) of
Δ7TNFR2 was tenfold lower than that of etanercept recovered from mouse serum. In vitro,
etanercept not exposed to the in vivo environment, or recombinant human or mouse Δ7TNFR2
protein, had equal EC50 values against mouse TNF-α (Supplementary Table S1). These results
likely reflect that, in vivo, etanercept was subjected to degradation that reduced its activity,
while the SSO continuously induced fresh Δ7TNFR2 into the serum, replacing degraded or
inactivated protein. Overall, the data suggest that, compared to injections of exogenous
etanercept, the SSO-induced Δ7TNFR2 protein, continuously expressed from the endogenous
gene, is tenfold more potent in the serum of treated mice. Note, however, that etanercept is a
humanized protein, and has greater pharmacokinetic properties in humans than in mice.
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SSO3274 treatment in hepatitis and arthritis mouse models
The SSO-induced Δ7TNFR2 protein was next tested for its anti–TNF-α activity in a mouse
model of inflammatory liver disease. Injection of galactosamine (GalN) followed by TNF-α
leads to rapid onset of liver inflammation.23 Galactosamine depletes intracellular UTP,26
leading to transcription inhibition and metabolic inactivation in hepatocytes, thus sensitizing
the liver to the toxic effects of TNF-α. Serum levels of released liver enzymes, alanine
aminotransferase (ALT) and aspartate aminotransferase (AST), provide a quantitative measure
of hepatocyte damage.27
Mice were injected IP once daily for 10 days with saline, control LNA SSO3083, or LNA
SSO3274 at 25 mg/kg/day. GalN and TNF-α were then administered (Figure 4a), which
induced peak serum concentration of AST and ALT 24–28 hours later (ref. 28 and
Supplementary Figure S6). Saline injections had no effect; 28 hours after GalN/TNF treatment,
there was up to a 20-fold serum increase in levels of both AST and ALT over background
(Figure 4b and c, white bars). In contrast, in LNA SSO3274–injected mice there was no increase
in the ALT/AST levels (Figure 4b, black bars), indicating that the active SSO protected the
liver from the TNF-α insult and prevented liver damage. Treatment with SSO3274 also
prevented leukocyte infiltration into the liver, indicating prevention of the inflammation (see
Figure 4d). The effects were sequence specific, as there was no protection and no statistically
or biologically significant difference (P > 0.2, saline versus SSO3083, ALT or AST) between
the effects of saline and the control SSO3083 (Figure 4c). SSO3083 is targeted to human β-
globin, and like SSO3272, which is targeted to TNFR2 but yields no splice switching (Figure
2), and induced no Δ7TNFR2 protein or anti–TNF-α activity in vivo.
Etanercept was also examined in the TNF-α-induced hepatitis model. A single dose, either 20
μg or 20 ng, intravenously (IV), predicted to produce ∼10 μg/ml and 10 ng/ml of etanercept
in the blood, respectively, was administered 5 hours before GalN/TNF injection. The latter is
equal to the concentration of Δ7TNFR2 achieved after SSO3274 injection (Figure 2b). The
results (Supplementary Figure S7) show that while injection of 20 μg etanercept prevented
ALT/AST induction, 20 ng had no effect, suggesting that at comparable concentrations,
SSO3274-induced Δ7TNFR2 protein was more potent in mice than etanercept.
LNA SSO3274 was also examined in the CIA mouse model of RA, in which two injections of
bovine collagen (CII) are given at days 0 and 21 (ref. 24). The first CII injection elicits an initial
immune reaction and establishes the memory response, while the booster (day 21) triggers the
memory response, resulting in acute inflammation of the joints. The CIA model is TNF-α
dependent, and disease onset begins at day 25 with a rapid increase in paw swelling, which
plateaus by days 50–65.
For treating CIA, mice were injected once daily with LNA SSO3274 at 25 mg/kg/day IP for
5 or 10 days (Figure 5a). The resulting total SSO doses, 3 and 6 mg respectively, induce
Δ7TNFR2 protein in DBA/1 mice, required for CIA experiments, in a dose-dependent manner
(Supplementary Figure S8). The SSO treatment was initiated at day 11, after the first CII
injection has activated memory effector lymphocytes and induced IgM and IgG antibodies.
Proportional to the total dose, SSO3274 induced 2,000 and 4,000 pg/ml of Δ7TNFR2 protein
at 5- and 10-day treatments, respectively (Figure 5b). These levels are lower in the DBA/1
mice than those in previously used FVB/N mice (∼10,000 pg/ml, Figure 2b). Nevertheless, in
both groups, the Δ7TNFR2 protein and its anti–TNF-α activity (Figure 5c) persisted in the
serum until at least day 50 of the CIA, 30 days after the last injection of SSO.
The 10-day SSO treatment ending on day 20 delayed significant paw swelling and clinical
scores caused by CIA for 14 days (days 27–40) (Figure 5d and e), which remained below the
level of saline-injected control mice until day 45 of the experiment. The course of the disease
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was inversely related with the level of Δ7TNFR2 protein detected by ELISA in the sera of 10-
day treated mice (Figure 5d versus b). Importantly, all groups of mice had nearly identical
incidence of disease (Supplementary Figure S9), confirming that SSO treatment did not prevent
disease, but suppressed its severity until day 45. The 5-day SSO treatment was ineffective,
because of lower, evidently insufficient, production of Δ7TNFR2 protein.
SSO3274 dose-maintenance
On the basis of Figure 2b, which shows persistence of Δ7TNFR2 for 27 days after SSO
injections, we hypothesized that once significant levels of Δ7TNFR2 were achieved by several
daily doses, they could be maintained by less frequent dosing. Thus, groups of FVB/N mice
were injected with a 5-day loading dose, followed by a single SSO injection every 2nd, 3rd,
4th, or 5th day (maintenance dose), for up to 37 days thereafter. All groups (Figure 6a) show
a robust induction of Δ7TNFR2 protein at day 1 post-loading dose. Mice that received a
maintenance dose every 5th day (Figure 6a, white bars) maintained high levels of Δ7TNFR2
for at least 37 days, compared with decreases in protein seen by day 27 without maintenance
dosing (Figure 2b). Impressively, mice receiving maintenance doses every 4th, 3rd, or 2nd day
showed increased Δ7TNFR2 serum levels. The major implications of these data are that (i)
high levels of Δ7TNFR2 protein can be maintained or enhanced by relatively infrequent SSO
dosing, and therefore it is a feasible treatment for chronic inflammation and (ii) that periodic
dosing does not lead to decreased activity of the SSO with time. This confirms our findings
that SSO-mediated induction of Δ7TNFR2 does not elicit an immune response against the
protein (Supplementary Figure S10).
Δ7TNFR2 induction in primary human hepatocytes
SSO3274 is mouse specific and cannot be used for clinical development. Therefore, a panel
of LNA SSOs, targeted toward skipping of human TNFR2 exon 7, was synthesized and tested
in primary human hepatocytes, the clinical target site of SSO action. These SSOs induced
soluble human Δ7TNFR2 protein in the media of treated cells (Figure 6b), with SSO3378,
3379, and 3384 shifting splicing >75%. Importantly, the human target sequences of these SSOs
are identical to those in Rhesus macaques, and thus their potency and toxicity can be evaluated
in detail in nonhuman primates before clinical trials.
Discussion
Previous studies have described a natural soluble secreted splice variant of TNFR2,
Δ7/8TNFR2, which is upregulated in the inflammatory state (∼300 pg/ml).3 However, no
protective effect of this splice variant has been demonstrated in RA patients. These levels are
evidently insufficient to alter the course of disease, and as the anti–TNF-α activity of
Δ7/8TNFR2 has not been determined,3 its physiological role is unclear. Here we show that
SSOs induced the Δ7TNFR2 protein, which has potent anti–TNF-α activity, to 10 ng/ml (Figure
2b), 30-fold higher than the Δ7/8TNFR2 in RA patients. Furthermore, while TNFR2 function
is downregulated in the inflammatory state by receptor shedding, expression at the transcription
level is often enhanced,29,30 increasing the potential Δ7TNFR2 yield of the SSO. Thus, SSOs
targeting TNFR2 may be effective in RA or hepatitis patients.
Mouse treatment with LNA SSO3274 for 10 days induced a pronounced, prolonged, dose-,
sequence-, and Δ7TNFR2 protein–dependent anti-inflammatory effect, which altered the
course of disease in two TNF-α-mediated disease models. Notably, SSO-induced Δ7TNFR2
appeared more potent than etanercept in the TNF-α-induced hepatitis (Figure 4, Supplementary
Figure S7). SSO3274 treatment before the onset of symptoms also delayed acute CIA, in which
two collagen injections are administered (Figure 5). The delayed course of the disease was
similar to that induced by etanercept in a milder mouse CIA model, in which just a single,
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initial collagen injection is given.31 In those experiments, etanercept was injected at 50 μg/
mouse once daily for 14 days, which should result in ∼25 μg/ml serum, a concentration 6,000-
fold higher than that of Δ7TNFR2 in our experiments (∼4 ng/ml).
In contrast to etanercept and other biologics, LNA SSO3274 itself has no anti–TNF-α activity,
but instead induces the sustained production of the Δ7TNFR2, TNF-α antagonist. Upon
systemic injection, LNA oligonucleotides are cleared within 1 hour from the circulation into
tissues,32 including liver, where they reside intact with a half-life of 2–3 weeks. Thus, they
continuously induce production of Δ7TNFR2 mRNA and protein, maintaining anti–TNF-α
activity in the circulation for ∼35 days (Figures 2b, 3a and 5). Furthermore, once the
therapeutic, steady-state level of Δ7TNFR2 is reached, Δ7TNFR2 production can be
maintained and enhanced by infrequent dosing (Figure 6a); this loading/maintenance regimen
was successfully used in clinical trials of a cholesterol-lowering antisense compound.33
SSOs may have several advantages over other drugs34,35 that are currently being used to
reduce the action of TNF-α. First, they induce a splice variant of the endogenous TNFR2 gene,
which may be better tolerated by patients and be less likely to have reduced efficacy over time
due to immune resistance. Second, the constant, persistent level of Δ7TNFR2 protein achieved
by SSO may allow less frequent drug dosing than required by other anti–TNF-α products. It
also avoids drastic changes in drug concentration seen with biologics,36 and therefore, the
negative effects on immune surveillance caused by anti–TNF-α treatment, a primary concern
with TNF-α Abs,37 may be avoided. Third, SSOs have the dual action of upregulating the
decoy-binding receptor in the peripheral circulation while downregulating the cell surface
receptor, which is particularly relevant in liver inflammation. Fourth, LNA SSOs may be orally
bioavailable;22 traditional antisense oligonucleotides containing the MOE modification have
been evaluated for oral bioavailability in clinical trials.38 Finally, because the oligonucleotides
are synthesized chemically, they would be less expensive to produce than current anti–TNF-
α protein drugs. Although the extent of these advantages remains to be determined,
development of these novel drugs will give physicians an additional therapeutic option for RA
patients, possibly including those (30% of all patients) that never see significant improvement
with the use of currently available drugs.39,40 Although certain sequences of LNA
oligonucleotides recently showed hepatotoxicity,41 we have seen no LNA-induced toxicity in
any of the mice we have treated,22 and a recent report shows LNA to be nontoxic in monkeys.
42
Materials and Methods
Reagents and cell culture
See Supplementary Materials and Methods
Mice and injections
FVB/N mice were used in all experiments except CIA, in which DBA/1 mice were used. IP
injections were 200 μl; tail-vein blood samples were 60 μl; LNA SSO injections were IP at 25
mg/kg/day once daily. To assay Δ7TNFR2 protein and anti–TNF-α activity, mice were bled
and sera collected after the SSO injections. At the time of killing, mice were asphyxiated with
carbon dioxide, blood was taken by cardiac puncture, and livers were removed. For 50 μg
etanercept injections, the drug was dissolved in sterile saline at 250 μg/ml. Lower dose dosing
solutions were diluted accordingly. Fresh solution was made each day of injection, which was
administered at 200 μl IP or 100 μl IV. All animal experiments were conducted in accordance
with Institutional Animal Care and Use Commitee guidelines.
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Mouse blood (∼60 μl) was clotted for 1 hour at 37 °C and centrifuged for 10 minutes at 14,000
rpm (Jouan BRA4i centrifuge; Jouan, Saint-Herblain, France). The concentration of mouse
Δ7TNFR2 induced by SSO3274 was quantified in 96-well plates coated using 100 μl of 10
μg/ml of a capturing antibody against C terminus (intracellular domain) of mouse TNFR2
(Abcam, Cambridge, MA), and Quantikine kit (R&D Systems, Minneapolis, MN), with an N-
terminal-specific TNFR2 primary antibody conjugated to horseradish peroxidase and substrate
solution (hydrogen peroxide and stabilized chromogen), according to the manufacturer's
instructions. As a standard, mouse Δ7TNFR2 obtained from the culture media of wild-type
HeLa cells transfected with plasmid expressing His-tagged Δ7TNFR2 and purified on Ni-
column was used (see Protein Preparation).
For etanercept (human) and human Δ7TNFR2 induced by SSOs in primary human hepatocyte
media, the Quantikine kit (R&D Systems) for human TNFR2 was used per the manufacturer's
instructions. Human Δ7TNFR2 protein was measured against the standard provided with the
kit; etanercept was measured against a standard curve of etanercept, with concentrations based
on the prescription details.
Reverse transcription–PCR
Approximately 5 mg of tissue, or cells in culture, was dissolved in 1 ml Tri Reagent (Molecular
Research Center, Cincinnati, OH) and total RNA was isolated per the manufacturer's
instructions. Approximately 200 ng of total RNA was subjected to reverse transcription–PCR
using the rTth polymerase (Applied Biosystems, Foster City, CA) per the manufacturer's
instructions. The mouse reverse primer was 5′-TCT CTC TGC AGG CAC AAG GG-3′; the
mouse forward primer was 5′-AAC GTG GTG GCC ATC CCT GG-3′. The human reverse
primer was 5′-CTT ATC GGC AGG CAA GTG AGG-3′; the human forward primer was 5′-
CGT TCT CCA ACA CGA CTT CA-3′. The PCR proceeded as follows: 95 °C, 60 seconds;
56 °C, 30 seconds; 72 °C, 60 seconds for 22 cycles total. The reaction solution contained Cy5-
labeled dCTP (GE Healthcare Bio-Sciences, Piscataway, NJ) for visualization (1 μl per 50
μl). The PCR products were separated on a 10% nondenaturing polyacrylamide gel, and Cy5-
labeled bands were visualized using a Typhoon 9400 Scanner (GE Healthcare Bio-Sciences,
Piscataway, NJ). Scans were quantified using ImageQuant (GE Healthcare Bio-Sciences,
Piscataway, NJ) software.
L929 cytotoxicity assay
Serum collected from mice was diluted to 10% in 100 μl L929 media, plus 1 μg/ml actinomycin
D and 0.1 ng/ml mouse TNF-α for 30 minutes. This mixture was then applied to the L929 cells
plated in 96-well plates (104 cells per well). After 24 hours later, cell viability was assayed by
adding 20 μl MTS reagent (CellTiter 96 AQueous One Solution Reagent; Promega, Madison,
WI) and measuring optical density at 495 nm, normalized to cells treated with 10% serum from
untreated mice and without added actinomycin D or TNF-α. For dose–response experiments,
sera from SSO-treated mice were serially diluted with serum from untreated mice and the anti–
TNF-α activity was assayed, and plotted against the concentration of Δ7TNFR2, as determined
by Δ7TNFR2-specific ELISA. Etanercept recovered from treated mice was assayed in the same
fashion.
For pure etanercept, mouse and human Δ7TNFR2 studies, fresh protein was diluted in 100 μl
L929 media from 0.4 to 444 ng/ml, and incubated with 10% mouse serum from untreated mice
containing actinomycin D and TNF-α for 30 minutes before being applied to cells. EC50 values
were determined by standard nonlinear regression analysis using GraphPad Prizm (GraphPad
Software, San Diego, CA).
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L929 cell cytotoxicity assay with anti-TNFR2 antibody
Samples were prepared in 100 μl L929 media supplemented with 10% fetal bovine serum.
Mouse TNF-α, actinomycin D, and purified mouse Δ7TNFR2 (see Protein Preparation) were
added to a final concentration of 0.1 ng/ml, 1 μg/ml, and 2 ng/ml, respectively. Anti-mouse
sTNFR2 polyclonal antibody (R&D Systems, Minneapolis, MN) was added to each sample at
the indicated final concentration. The samples were then incubated for 30 minutes at room
temperature and evaluated in the L929 cytotoxicity assay as described earlier.
GalN/TNF
Mice were injected IP daily with either LNA SSO3274 (10 mice at 25 mg/kg/day) or saline
(15 mice) for 10 days, or once with etanercept IV. Five hours after etanercept or twenty-four
hours after the final SSO injection, all mice were injected IP with 20 mg galactosamine [D-(+)-
galactosamine hydrochloride] followed by 3 ng IV injection of mouse TNF-α 20 minutes later.
Twenty-eight hours after TNF-α injection, blood was taken and the mice were killed. ALT/
AST measurements were by the University of North Carolina Histology Core. Livers were
removed for paraffin embedding and hematoxylin & eosin staining, and slide mounting was
performed by the Pathology Core at University of North Carolina
(http://cancer.med.unc.edu/research/cores/facility.asp?facilityID=12). Images were taken
using an Axiovert microscope (Carl Zeiss, Thornwood, NY).
CIA
DBA/1 mice were immunized subcutaneously with bovine type II collagen subcutaneously
(100 μg in complete Freund's adjuvant on day 0 and 100 μg in incomplete Freund's adjuvant
on day 21), at the base of the tail using a 27G needle with a volume of 100 μl (1:1
adjuvant:collagen). Mice were assessed for general health daily for 3 days after immunization,
then every 3–4 days for weight, paw swelling, and global assessment of disease. Swelling at
the ankle of all four paws was measured with a caliper and the change in paw thickness from
the pretreatment baseline was recorded. Clinical index is a clinical measurement of the degree
of arthritis severity and takes into account arthritis that is present beyond the ankle swelling,
such as the toes or tenosynovium. Each paw was assessed by a blinded observer; maximum
score is 3 per paw for a total of 12 per mouse (Table 1).
Protein preparation
HeLa cells (0.5 × 106 cells per well in 6 wells) were transfected with 1.5 μg/well of plasmid
DNA coding a c-terminal His-tagged human or mouse Δ7TNFR2. Media were collected after
48 hours, filtered through a 1-μm filter, and loaded onto 1-ml HisTrap (Ni) column using a
Fast Protein Liquid Chromatography (GE Healthcare). The Δ7TNFR2 was eluted with 400
mmol/l imidazole buffer (20 mmol/l Tris pH = 7.5, 150 mmol/l NaCl, 400 mmol/l imidazole).
The fractions were pooled, concentrated and exchanged to phosphate-buffered saline with a
VivaSpin 20 (30,000 MWCO; Viva Science) centrifuge filter unit. The final protein
concentration was measured by ELISA as described earlier.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The Δ7TNFR2 splice variant
The full-length (FL), functional, membrane-bound tumor necrosis factor receptor 2 (TNFR2)
is translated from messenger RNA (mRNA) containing all 10 coding exons. Targeting of exon
7 in pre-mRNA with LNA SSOs (black bars) induces a soluble isoform, Δ7TNFR2, that lacks
a transmembrane domain (TM), retains the extracellular and intracellular domains (ECD and
ICD, respectively) and is secreted by cells. Importantly, the shed form of soluble TNFR2
contains only the ECD. Black, extracellular domain; white, transmembrane domain; gray,
intracellular domain. LNA, locked nucleic acid; SSOs, splice-switching oligonucleotides.
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Figure 2. Induction of Δ7TNFR2 by locked nucleic acid (LNA) SSO3274
(a) LNA splice-switching oligonucleotides (SSOs) targeted to mouse tumor necrosis factor
receptor 2 (TNFR2) pre-mRNA from 20 bp upstream to 20 bp downstream and including exon
7. Thick line, exon; thin line, intron; short lines, LNA SSOs. L929 cells were transfected with
the indicated SSOs at a final concentration of 50 nmol/l. After 24 hours, cells were lysed, RNA
was isolated and analyzed for splice switching by reverse transcription–PCR (RT-PCR). FL,
full-length TNFR2 messenger RNA (mRNA); Δ7, Δ7TNFR2 mRNA splice variant. (b) Mice
(n = 5 per group) were injected intraperitoneally with SSO3274 or control SSO3272 at 25 mg/
kg/day once daily for 5 days. Serum was collected 4 days before injections began (0) and at
the indicated number of days after the last SSO injection (gray). Top, samples were analyzed
by enzyme-linked immunosorbent assay. Bottom, mice were killed at indicated days and total
liver RNA was analyzed by RT-PCR for TNFR2 pre-mRNA splice switching. Each lane
represents analysis of liver RNA from a single treated mouse. Data for days 10 and 27 are from
separate experiments.
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Figure 3. Anti–TNF-α activity of Δ7TNFR2 protein
(a) LNA SSOs were administered to mice as described at 25 mg/kg/day once daily for 10 days.
The serum was collected 5 or 27 days after the last injection, diluted to 10% and applied to
L929 in the presence of actinomycin D and TNF-α (ActD/TNF-α). After 24 hours, cell viability
was determined using MTS assay and compared with controls. Ctr, cells treated with 10%
serum from untreated mice and no ActD/TNF; TNF, cells treated with 10% serum from
untreated mice and ActD/TNF; TNF +, cells treated with 10% serum from mice treated with
the indicated SSO and ActD/TNF. TNF + 3274 (n = 3), all other (n = 1). Note that serum from
SSO3272, 3083, and untreated mice yielded a reproducible lack of protection from TNF-α.
(b) Anti-TNFR2 antibodies (Abs) neutralize the anti–TNF-α effect of Δ7TNFR2. The L929
cytotoxicity assay was performed as described in a, except that the indicated concentrations
of an anti-TNFR2 Ab was added at the indicated concentrations. Ctr, L929 cell receiving no
ActD/TNF-α, anti-TNFR2 Ab, or Δ7TNFR2; Ab, cells receiving 200 ng/ml anti-TNFR2 Ab
only; TNF, cells receiving ActD/TNF-α only. (c) Half maximal effective concentration
(EC50) values calculated from a (see Materials and Methods). LNA, locked nucleic acid; SSO,
splice-switching oligonucleotide; TNF-α, tumor necrosis factor-α; TNFR2, TNF receptor 2.
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Figure 4. Tumor necrosis factor-α (TNF-α)-induced hepatitis model
(a) Mice were treated intraperitoneally with saline, control SSO3083 (see Figure 2a), or
Δ7TNFR2 inducing SSO3274 at 25 mg/kg once daily for 10 days. After 24 hours (day 0, hour
0), mice were injected with 20 mg galactosamine (GalN) followed by 3 ng TNF-α 20 minutes
later, which induces an acute inflammatory response in the liver. (b) The extent of hepatocyte
damage caused by the inflammatory insult is reflected by increased levels of liver enzymes,
aspartate aminotransferase (AST) and alanine aminotransferase (ALT), released by hour 28
into the blood stream of control, saline-injected, mice (white bars). Treatment with locked
nucleic acid SSO3274 (black bars) prevents liver damage and enzyme release. (c) Control
SSO3083 (black bars) showed no preventative effect. Saline treatment (n = 15); splice-
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switching oligonucleotide (SSO) treatment (n = 10). P values for saline versus control
SSO3083 in ALT or AST were P > 0.2. (d) Livers from mice treated as in b were removed at
the time of killing (28 hours), imbedded in paraffin and stained with hematoxylin & eosin.
Arrows, sites of inflammatory infiltrate. TNFR2, TNF receptor 2.
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Figure 5. Locked nucleic acid (LNA) SSO3274 activity in collagen-induced arthritis (CIA) mice
(a) Time course of CIA model. Mice (n = 10) were treated with either saline from day 11–20
(saline) or 25 mg/kg/day of SSO3274 from day 11–15 or 11–20 (SSO 5D and 10D,
respectively). (b) Serum was collected from mice on the indicated day of the experiment and
analyzed by Δ7TNFR2 specific enzyme-linked immunosorbent assay, or (c) anti–TNF-α L929
cytotoxicity assay. (d) Administration of LNA SSO3274 for 10 days delayed and reduced the
onset and extent of the course of the disease as measured by paw swelling or (e) clinical index.
Measurements in d and e were performed as described in Materials and Methods. SSO, splice-
switching oligonucleotide; TNF-α, tumor necrosis factor-α; TNFR2, TNF receptor 2.
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Figure 6. Therapeutic potential of Δ7TNFR2 inducing splice-switching oligonucleotide (SSO)
(a) Mice were injected with a loading dose of 5 days of once daily 25 mg/kg/day SSO3274,
followed by a single 25 mg/kg maintenance dose every 2nd, 3rd, 4th, or 5th day for 37 days.
Δ7TNFR2 was measured in serum samples as in previous figures. (b) The indicated SSO was
delivered to primary human hepatocytes by cationic lipid transfection at a final concentration
of ∼30 nmol/l. Total RNA and extracellular media were collected 72 hours after transfection,
and total RNA was analyzed by reverse transcription–PCR and medium was analyzed by
enzyme-linked immunosorbent assay (ELISA) for Δ7TNFR2 messenger RNA and protein,
respectively. Note that this ELISA detects both the shed form and the Δ7TNFR2 form, thus
control (3083)-treated cells show a small background of shed tumor necrosis factor receptor 2
(TNFR2) extracellular domain. FL, full length.
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Table 1
Clinical Scoring
Arthritis score clinical presentation
0 Normal paw, no arthritis
1 Mild but definite swelling and/or redness of one major joint (wrist or ankle) or toe involvement (any number)
2 Moderate redness and swelling of wrist or ankle ± any number of toes
3 Maximal redness and swelling of entire paw including toes ± ankylosis
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